Atlas Trials

Taizhou Hanzhong biomedical co. LTD

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Taizhou Hanzhong biomedical co. LTD

RecordFirmDate
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer (NCT05652894)Taizhou Hanzhong biomedical co. LTD2023-02-28
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver (NCT05647954)Taizhou Hanzhong biomedical co. LTD2022-12-31
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) (NCT04741165)Taizhou Hanzhong biomedical co. LTD2021-01-07
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) (NCT04574817)Taizhou Hanzhong biomedical co. LTD2020-12-28
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NCT04750083)Taizhou Hanzhong biomedical co. LTD2020-09-25
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT04738630)Taizhou Hanzhong biomedical co. LTD2020-09-25
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer (NCT04486651)Taizhou Hanzhong biomedical co. LTD2020-09-16
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors (NCT04825392)Taizhou Hanzhong biomedical co. LTD2019-09-05
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer (NCT04750382)Taizhou Hanzhong biomedical co. LTD2019-07-15
A Study of HX008 for the Treatment of Patients With Malignant Melanoma (NCT04749485)Taizhou Hanzhong biomedical co. LTD2018-11-08

Track Taizhou Hanzhong biomedical co. LTD automatically

Every clearance here is in the API, with alerts when new ones post.